Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aadi Bioscience, Inc. AADI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
28/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.63
-20.5%

Aadi Bioscience, Inc. (AADI) is a Biotechnology company in the Healthcare sector, currently trading at $2.05. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is AADI = $2 (-20.5% upside).

Financials: revenue is $7M, -1.9%/yr average growth. Net income is $21M (loss), growing at +18.5%/yr. Net profit margin is -288.3% (negative). Gross margin is 0% (-91.2 pp trend).

Balance sheet: total debt is $0 against $136M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 10.26 (strong liquidity). Debt-to-assets is 0%. Total assets: $151M.

Analyst outlook: 3 / 6 analysts rate AADI as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 28/100 (Fail), Income 10/100 (Fail).

$1.63
▼ 20.49% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Aadi Bioscience, Inc., the average price target is $1.63, with a high forecast of $1.75, and a low forecast of $1.50.
Highest Price Target
$1.75
Average Price Target
$1.63
Lowest Price Target
$1.50

AADI SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 28/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AADI

✗
VALUE Fail
10/100
AADI trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying -2.4% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
AADI: -1.9%/yr revenue is, +18.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet AADI: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 10.26 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✗
FUTURE Fail
28/100
Analyst outlook: 3 / 6 analysts rate AADI as buy (50%). Analyst consensus target is $2 (-2.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
AADI: Net profit margin is -288.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.21-3.812
Volume62.61K
Avg Volume (30D)200.71K
Market Cap$94.89M
Beta (1Y)0.34
Share Statistics
EPS (TTM)-0.03
Shares Outstanding$618.87M
IPO Date2018-02-16
Employees53
CEODavid J. Lennon
Financial Highlights & Ratios
Revenue (TTM)$7.15M
EBITDA$-114.4M
Net Income$-20.6M
Operating Income$-114.4M
Total Cash$145.7M
Net Debt$-37.57M
Total Assets$150.83M
Price / Earnings (P/E)-61.6
Price / Sales (P/S)13.28
Analyst Forecast
1Y Price Target$1.63
Target High$1.75
Target Low$1.50
Upside-20.7%
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS00032Q1040

Price Chart

Track all markets on TradingView
AADI
Aadi Bioscience, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.21 52WK RANGE 3.81

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 RARE
RARE
Ultragenyx Pharmaceutical Inc.
$24.57
+3.98%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 KURA
KURA
Kura Oncology, Inc.
$9.14
+4.82%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message